Delayed-Action Preparations
"Delayed-Action Preparations" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Dosage forms of a drug that act over a period of time by controlled-release processes or technology.
| Descriptor ID |
D003692
|
| MeSH Number(s) |
D26.255.210 E02.319.300.253
|
| Concept/Terms |
Controlled-Release Preparations- Controlled-Release Preparations
- Controlled Release Preparations
- Controlled-Release Preparation
- Controlled-Release Formulations
- Controlled Release Formulations
- Controlled-Release Formulation
Sustained-Release Preparations- Sustained-Release Preparations
- Sustained-Release Preparation
- Extended Release Preparations
- Extended Release Preparation
- Slow Release Formulation
- Sustained Release Formulations
- Sustained Release Formulation
- Extended Release Formulations
- Extended Release Formulation
|
Below are MeSH descriptors whose meaning is more general than "Delayed-Action Preparations".
Below are MeSH descriptors whose meaning is more specific than "Delayed-Action Preparations".
This graph shows the total number of publications written about "Delayed-Action Preparations" by people in this website by year, and whether "Delayed-Action Preparations" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2004 | 2 | 0 | 2 |
| 2005 | 0 | 3 | 3 |
| 2007 | 0 | 3 | 3 |
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Delayed-Action Preparations" by people in Profiles.
-
Intraarticular slow-release triamcinolone acetate reduces allodynia in an experimental mouse knee osteoarthritis model. Gene. 2016 Oct 10; 591(1):1-5.
-
Delivering heparin-binding insulin-like growth factor 1 with self-assembling peptide hydrogels. Tissue Eng Part A. 2015 Feb; 21(3-4):637-46.
-
Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release. J Affect Disord. 2010 Nov; 126(3):420-9.
-
Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy. J Clin Psychiatry. 2008 Mar; 69(3):400-5.
-
Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study. J Clin Psychiatry. 2007 Jul; 68(7):1014-23.
-
A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology (Berl). 2007 Oct; 194(2):233-42.
-
Will insomnia treatments produce overall cost savings to commercial managed-care plans? A predictive analysis in the United States. Curr Med Res Opin. 2007 Jun; 23(6):1431-43.
-
A multi-scale stochastic drug release model for polymer-coated targeted drug delivery systems. J Control Release. 2006 Jan 10; 110(2):314-322.
-
Local application of rhTGF-beta2 enhances peri-implant bone volume and bone-implant contact in a rat model. Bone. 2005 Jul; 37(1):55-62.
-
Morning melatonin has limited benefit as a soporific for daytime sleep after night work. Chronobiol Int. 2005; 22(5):873-88.